Abstract
We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.
Keywords:
ALK rearrangement; Lorlatinib; Lung cancer; Pulmonary hypertension; Tyrosine kinase inhibitor.
Copyright © 2018 Elsevier B.V. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminopyridines
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Drug-Related Side Effects and Adverse Reactions / diagnosis*
-
Dyspnea
-
Female
-
Humans
-
Hypertension, Pulmonary / diagnosis*
-
Hypertension, Pulmonary / etiology
-
Lactams
-
Lactams, Macrocyclic / adverse effects*
-
Lactams, Macrocyclic / therapeutic use
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / drug therapy
-
Male
-
Middle Aged
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrazoles
-
Vascular Resistance / drug effects
-
Walk Test
-
Withholding Treatment
Substances
-
Aminopyridines
-
Antineoplastic Agents
-
Lactams
-
Lactams, Macrocyclic
-
Protein Kinase Inhibitors
-
Pyrazoles
-
lorlatinib